View in EDS

Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers.

Saved in:
Bibliographic Details
Title: Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers.
Authors: Corlett A; Department of Nuclear Medicine, The Royal Melbourne Hospital, Parkville, Victoria, 3000, Australia., Pinson JA; The Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia., Rahimi MN; The Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia., Zuylekom JV; Models of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia., Cullinane C; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.; The Centre for Molecular Imaging and Translational Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia., Blyth B; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.; Models of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia., Thompson PE; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria 3052, Australia., Hutton CA; School of Chemistry, The University of Melbourne, Melbourne, Victoria 3010, Australia., Roselt PD; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; The Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia., Haskali MB; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; The Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.
Source: Journal of medicinal chemistry [J Med Chem] 2023 Aug 10; Vol. 66 (15), pp. 10289-10303. Date of Electronic Publication: 2023 Jul 26.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37493526
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Corlett+A%22">Corlett A</searchLink>; Department of Nuclear Medicine, The Royal Melbourne Hospital, Parkville, Victoria, 3000, Australia.<br /><searchLink fieldCode="AU" term="%22Pinson+JA%22">Pinson JA</searchLink>; The Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.<br /><searchLink fieldCode="AU" term="%22Rahimi+MN%22">Rahimi MN</searchLink>; The Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.<br /><searchLink fieldCode="AU" term="%22Zuylekom+JV%22">Zuylekom JV</searchLink>; Models of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.<br /><searchLink fieldCode="AU" term="%22Cullinane+C%22">Cullinane C</searchLink>; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.; The Centre for Molecular Imaging and Translational Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.<br /><searchLink fieldCode="AU" term="%22Blyth+B%22">Blyth B</searchLink>; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.; Models of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.<br /><searchLink fieldCode="AU" term="%22Thompson+PE%22">Thompson PE</searchLink>; Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria 3052, Australia.<br /><searchLink fieldCode="AU" term="%22Hutton+CA%22">Hutton CA</searchLink>; School of Chemistry, The University of Melbourne, Melbourne, Victoria 3010, Australia.<br /><searchLink fieldCode="AU" term="%22Roselt+PD%22">Roselt PD</searchLink>; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; The Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.<br /><searchLink fieldCode="AU" term="%22Haskali+MB%22">Haskali MB</searchLink>; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; The Radiopharmaceutical Research Laboratory, The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229716531%22">Journal of medicinal chemistry</searchLink> [J Med Chem] 2023 Aug 10; Vol. 66 (15), pp. 10289-10303. <i>Date of Electronic Publication: </i>2023 Jul 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Chemical+Society%22">American Chemical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9716531 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1520-4804 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200222623%22">00222623 </searchLink><i>NLM ISO Abbreviation: </i>J Med Chem <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37493526
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1021/acs.jmedchem.3c00377
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 10289
    Titles:
      – TitleFull: Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Corlett A
      – PersonEntity:
          Name:
            NameFull: Pinson JA
      – PersonEntity:
          Name:
            NameFull: Rahimi MN
      – PersonEntity:
          Name:
            NameFull: Zuylekom JV
      – PersonEntity:
          Name:
            NameFull: Cullinane C
      – PersonEntity:
          Name:
            NameFull: Blyth B
      – PersonEntity:
          Name:
            NameFull: Thompson PE
      – PersonEntity:
          Name:
            NameFull: Hutton CA
      – PersonEntity:
          Name:
            NameFull: Roselt PD
      – PersonEntity:
          Name:
            NameFull: Haskali MB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 08
              Text: 2023 Aug 10
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1520-4804
          Numbering:
            – Type: volume
              Value: 66
            – Type: issue
              Value: 15
          Titles:
            – TitleFull: Journal of medicinal chemistry
              Type: main
ResultId 1